Oncology News | pharmaphorum

News

Susan Galbraith, executive vice-president, Oncology R&D, AstraZeneca

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

The overall survival (OS) data has come in from the TROPION-Lung01 study of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in lung cancer – and the res

News

ASCO: AffyImmune claims a first with CAR-T for solid tumours

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy.

News

ASCO: Merus bispecific garners attention after abstract drop

Among the myriad of new studies highlighted in the newly published ASCO abstracts, Merus’ seems to have struck a chord with its phase 2 trial of bispecific antibody petosemtamab in he

News

ADC developer Pheon raises $120m, and other bio financings

This week’s round-up of biotech financings is led by a $120 million round for UK-based antibody-drug conjugate (ADC) developer Pheon, with SixPeaks also pulling in nine fi

News

AstraZeneca sets lofty target of $80bn in revenues by 2030

AstraZeneca easily delivered on chief executive Pascal Soriot’s pledge to deliver $45 billion in revenues by 2023, set a decade earlier as he fended off a takeover bid by

News

AstraZeneca unveils plan for $1.5bn ADC plant in Singapore

AstraZeneca is backing up its considerable investment in antibody-drug conjugates (ADCs) for cancer with the construction of a $1.5 billion new facility in Singapore to ma

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

ASCO: AffyImmune claims a first with CAR-T for solid tumours

ASCO: Merus bispecific garners attention after abstract drop

ADC developer Pheon raises $120m, and other bio financings

AstraZeneca sets lofty target of $80bn in revenues by 2030

AstraZeneca unveils plan for $1.5bn ADC plant in Singapore

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks